BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 22692509)

  • 1. The arsenic-based cure of acute promyelocytic leukemia promotes cytoplasmic sequestration of PML and PML/RARA through inhibition of PML body recycling.
    Lång E; Grudic A; Pankiv S; Bruserud O; Simonsen A; Bjerkvig R; Bjørås M; Bøe SO
    Blood; 2012 Jul; 120(4):847-57. PubMed ID: 22692509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PCGF2 negatively regulates arsenic trioxide-induced PML-RARA protein degradation via UBE2I inhibition in NB4 cells.
    Jo S; Lee YL; Kim S; Lee H; Chung H
    Biochim Biophys Acta; 2016 Jul; 1863(7 Pt A):1499-509. PubMed ID: 27030546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment.
    Goto E; Tomita A; Hayakawa F; Atsumi A; Kiyoi H; Naoe T
    Blood; 2011 Aug; 118(6):1600-9. PubMed ID: 21613260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein.
    Isakson P; Bjørås M; Bøe SO; Simonsen A
    Blood; 2010 Sep; 116(13):2324-31. PubMed ID: 20574048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3.
    Jeanne M; Lallemand-Breitenbach V; Ferhi O; Koken M; Le Bras M; Duffort S; Peres L; Berthier C; Soilihi H; Raught B; de Thé H
    Cancer Cell; 2010 Jul; 18(1):88-98. PubMed ID: 20609355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure.
    Ablain J; Rice K; Soilihi H; de Reynies A; Minucci S; de Thé H
    Nat Med; 2014 Feb; 20(2):167-74. PubMed ID: 24412926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARα protein degradation.
    Wang QQ; Zhou XY; Zhang YF; Bu N; Zhou J; Cao FL; Naranmandura H
    Oncotarget; 2015 Sep; 6(28):25646-59. PubMed ID: 26213848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel treatment of acute promyelocytic leukemia: As₂O₃, retinoic acid and retinoid pharmacology.
    Zhu G
    Curr Pharm Biotechnol; 2013; 14(9):849-58. PubMed ID: 24433507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.
    Zhang XW; Yan XJ; Zhou ZR; Yang FF; Wu ZY; Sun HB; Liang WX; Song AX; Lallemand-Breitenbach V; Jeanne M; Zhang QY; Yang HY; Huang QH; Zhou GB; Tong JH; Zhang Y; Wu JH; Hu HY; de Thé H; Chen SJ; Chen Z
    Science; 2010 Apr; 328(5975):240-3. PubMed ID: 20378816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell-cycle regulation and dynamics of cytoplasmic compartments containing the promyelocytic leukemia protein and nucleoporins.
    Jul-Larsen A; Grudic A; Bjerkvig R; Bøe SO
    J Cell Sci; 2009 Apr; 122(Pt 8):1201-10. PubMed ID: 19339552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Varying responses of PML-RARA with different genetic mutations to arsenic trioxide.
    Liu J; Zhu HH; Jiang H; Jiang Q; Huang XJ
    Blood; 2016 Jan; 127(2):243-50. PubMed ID: 26537301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function.
    Bercier P; Wang QQ; Zang N; Zhang J; Yang C; Maimaitiyiming Y; Abou-Ghali M; Berthier C; Wu C; Niwa-Kawakita M; Dirami T; Geoffroy MC; Ferhi O; Quentin S; Benhenda S; Ogra Y; Gueroui Z; Zhou C; Naranmandura H; de Thé H; Lallemand-Breitenbach V
    Cancer Discov; 2023 Dec; 13(12):2548-2565. PubMed ID: 37655965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations at proximal cysteine residues in PML impair ATO binding by destabilizing the RBCC domain.
    Dubey S; Mishra N; Shelke R; Varma AK
    FEBS J; 2024 Apr; 291(7):1422-1438. PubMed ID: 38129745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Curing APL through PML/RARA degradation by As2O3.
    Lallemand-Breitenbach V; Zhu J; Chen Z; de Thé H
    Trends Mol Med; 2012 Jan; 18(1):36-42. PubMed ID: 22056243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clearance of PML/RARA-bound promoters suffice to initiate APL differentiation.
    Vitaliano-Prunier A; Halftermeyer J; Ablain J; de Reynies A; Peres L; Le Bras M; Metzger D; de Thé H
    Blood; 2014 Dec; 124(25):3772-80. PubMed ID: 25258343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promyelocytic leukemia nuclear bodies support a late step in DNA double-strand break repair by homologous recombination.
    Yeung PL; Denissova NG; Nasello C; Hakhverdyan Z; Chen JD; Brenneman MA
    J Cell Biochem; 2012 May; 113(5):1787-99. PubMed ID: 22213200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sumoylation of the Tumor Suppressor Promyelocytic Leukemia Protein Regulates Arsenic Trioxide-Induced Collagen Synthesis in Osteoblasts.
    Xu WX; Liu SZ; Wu D; Qiao GF; Yan J
    Cell Physiol Biochem; 2015; 37(4):1581-91. PubMed ID: 26517826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients.
    Lou Y; Ma Y; Sun J; Ye X; Pan H; Wang Y; Qian W; Meng H; Mai W; He J; Tong H; Jin J
    Ann Hematol; 2015 Nov; 94(11):1829-37. PubMed ID: 26294332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting HDAC3 to overcome the resistance to ATRA or arsenic in acute promyelocytic leukemia through ubiquitination and degradation of PML-RARα.
    Dai B; Wang F; Wang Y; Zhu J; Li Y; Zhang T; Zhao L; Wang L; Gao W; Li J; Zhu H; Li K; Hu J
    Cell Death Differ; 2023 May; 30(5):1320-1333. PubMed ID: 36894687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of SUMO in RNF4-mediated promyelocytic leukemia protein (PML) degradation: sumoylation of PML and phospho-switch control of its SUMO binding domain dissected in living cells.
    Percherancier Y; Germain-Desprez D; Galisson F; Mascle XH; Dianoux L; Estephan P; Chelbi-Alix MK; Aubry M
    J Biol Chem; 2009 Jun; 284(24):16595-16608. PubMed ID: 19380586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.